Inspired by our preclinical findings, we posited that human melanomas with attenuated IFN-γ signaling would have reduced expression of T cell signature genes, including prototypical surface markers for T cells (CD3, CD4, and CD8), effector molecules (IFNG, GZMB, perforin (PRF1), and TNF), and MHC molecules (MHC I: HLA-A, HLA-B, and HLA-C; MHC II: HLA-DRA). The gene discussed is CD4; the disease is melanoma.